Investor Relations
Zytrell Skin Solutions is a US-based skincare company specialising in science-backed, botanical-infused acne treatments built on salicylic acid.
For accredited investors or strategic parties interested in learning more about Zytrell Skin Solutions, please contact our CFO, Luke Marchese, at lmarchese@zytrell.com.
Our signature Acne Treatment Cream, launched in May 2026, combines 2% salicylic acid with skin-soothing botanicals including aloe, tea tree oil, and resveratrol. It is designed to target everything from whiteheads and blackheads to hormonal acne while protecting the skin barrier.
Z-Clear™ Technology
Proprietary, research-backed technology — with a licensed patent in part from Columbia University — designed to deliver active ingredients effectively while remaining gentle enough for sensitive skin.
Our Mission
We believe in clean, safe, and effective skincare for everyone.
Brand Highlights
- Sensitive-Skin Friendly: Formulated without benzoyl peroxide or parabens to minimise redness, peeling, and irritation.
- Fast Results: Visible improvements — such as reduced redness and clearer congestion — within 24–48 hours.
- Trusted Manufacturing: Formulated in US-based, FDA-registered, GMP-compliant facilities.
- Science-Backed: Botanical actives delivered through proprietary Z-Clear™ technology.
Leadership Team
Eugene Ciolfi
President & Chief Executive OfficerSeasoned executive with a blend of Rx, OTC, and drug-delivery experience, and over 35 years of progressive leadership success with mid-market, niche players. C-suite strategy experience, previously serving in executive capacities with Bausch & Lomb, DPT Laboratories, and MedPharm.
Luke Marchese
Chief Financial Officer15 years of experience across investment banking and corporate development, including with J.P. Morgan Capital Markets & Derivatives and Williams Companies (NYSE: WMB) Strategic Development. B.A. in Markets & Management from Duke University; alumnus of Columbia University’s CFO programme.
Roberto Darienzo
Chief Operating Officer40+ years’ experience in Pharma/Biotech. Member of Operation Warp Speed for the US Government, consultant, and founder & CEO of Dynami Pharma. Held Sr VP / COO positions in companies including Merck, Schering-Plough, Sanofi, Aventis, Halo G&W, Ferring, and PAI Pharma.
Dan Ratiu
Chief Technology Officer20+ years’ experience in Pharma operations, technical services, validation engineering, project management, and drug scale-up development. Partner at Dynami Pharma and Care Pro Solutions; previously held positions at Teligent, G&W Labs, PAI Pharma, and Torrent.
Board of Directors
Eugene Ciolfi
Executive Board Member · President & CEOSeasoned executive with a blend of Rx, OTC, and drug-delivery experience, and over 35 years of progressive leadership success with mid-market, niche players. Previously served in executive capacities with Bausch & Lomb, DPT Laboratories, and MedPharm.
Anthony Marchese
Executive Chairman35+ years’ experience, currently President of Marchese Management Company LLC, a strategic advisory firm serving public and soon-to-be-public companies in board direction & policy, corporate governance, investor relations, and crisis management. Former Head of Preferred Stock at Oppenheimer. Educated at the Chicago School of Business. Served in the U.S. Army Security Agency.
Leonard Osser
Board MemberHighly experienced investor with 40+ years’ experience. Managing Member of U.S. Asian Consulting Group, LLC, a consultancy specialising in distressed and turnaround situations across public and private markets. Serves as a special consultant to the board of directors of Nexalin Technology, Inc., where he is also Director of International Operations.
Roberto Darienzo
Board Member · Chief Operating Officer40+ years’ experience in Pharma/Biotech. Member of Operation Warp Speed for the US Government, consultant, and founder & CEO of Dynami Pharma. Held Sr VP / COO positions at companies including Merck, Schering-Plough, Sanofi, Aventis, Halo G&W, Ferring, and PAI Pharma.
Advisory Board
Joseph (“Joe”) Gordon
Advisory Board Member35+ years’ experience, most recently as President of Bausch + Lomb’s Global Consumer Healthcare, Surgical & Vision Care businesses — responsible for $3.8bn in annual sales and leadership of ~3,500 employees across global operations. Before B+L, spent 20 years with Wyeth (until its acquisition by Pfizer) working on brands such as Advil, Centrum, and Robitussin.
Abe Scheer
Advisory Board Member30+ years of wealth management and banking experience across various brokerage firms, raising venture capital for hundreds of companies. Former Managing Director at Maxim Securities and founder of Eastwalk Consultants, a provider of corporate capital-raising solutions. CPA, formerly with Coopers & Lybrand.
Corporate & Sustainability (ESG)
“At Zytrell Skin Solutions, our purpose is to improve the quality of patient lives. We are dedicated to creating a healthier world by driving innovation and ensuring equitable access to our therapies, regardless of geography or socioeconomic status. We maintain the highest standards of safety, quality, and ethical conduct throughout our product lifecycles.”
Our success relies on the talent and dedication of our team. We cultivate an inclusive, diverse, and safe work environment that empowers our people to innovate. We are equally committed to our local and global communities through transparent business practices and strategic partnerships that address unmet medical needs.
We hold ourselves to the highest standards of corporate governance, integrity, and transparency. We embed accountability at every level of our organisation to ensure ethical decision-making, responsible research and development practices, and strict compliance with global healthcare regulations.
In the News
